Literature DB >> 30074466

Clinical and biological significance of adamantinomatous craniopharyngioma with CTNNB1 mutation.

Takuma Hara1, Hiroyoshi Akutsu1, Shingo Takano1, Hiroyoshi Kino1, Eiichi Ishikawa1, Shuho Tanaka2, Hidetaka Miyamoto2, Noriaki Sakamoto3, Keiichiro Hattori4, Mamiko Sakata-Yanagimoto4, Shigeru Chiba4, Takashi Hiyama5, Tomohiko Masumoto5, Akira Matsumura1.   

Abstract

OBJECTIVE: The Wnt/β-catenin signaling pathway is strongly implicated in the pathogenesis of adamantinomatous craniopharyngioma (adaCP). However, there is no evidence that the CTNNB1 mutation activates the target gene of Wnt/β-catenin signaling, and it is unknown whether it affects the tumorigenesis of adaCP. To assess the effect of the CTNNB1 mutation of adaCP, the authors analyzed the correlation between the mutation and clinical, radiological, pathological, and biological findings.
METHODS: Between 2003 and 2015, 42 patients (24 male and 18 female, median age 42 years) with either papillary craniopharyngioma (papCP) or adaCP underwent tumor resection at the authors' institution. BRAF V600E and CTNNB1 in papCP and adaCP samples were sequenced by next-generation sequencing and the Sanger method, and mRNA expression levels of Axin2 and BMP4 were evaluated by RT-PCR. Axin2, BMP4, β-catenin, and BRAF expression were evaluated by immunohistochemistry. Other data were collected from clinical reports.
RESULTS: The BRAF V600E mutation was detected in all 10 cases of papCP (100%). CTNNB1 exon 3 mutations were detected in 21 of 31 (68%) cases of adaCP, excluding 1 case for which there were no available sequence data. The mRNA expression level of Axin2 was significantly higher in adaCPs with a CTNNB1 mutation than in those without (p < 0.05). The immunohistochemical findings of Axin2 and BMP4 did not correlate with CTNNB1 mutation positivity. When patients who received adjuvant radiation therapy were excluded, progression-free survival was shorter in the mutation-positive group than in the mutation-negative group (log-rank test, p = 0.031). Examination of clinical characteristics and immunohistochemical findings of adaCPs showed that there was no significant correlation between CTNNB1 mutation positivity and age, sex, tumor volume, gross-total resection, optic tract edema, calcification, or T1 signal intensity of cyst fluid on MRI, β-catenin, and MIB-1 index.
CONCLUSIONS: These results raise the possibility that the CTNNB1 mutation in adaCP may be associated with disease recurrence, and genes related to the Wnt/β-catenin signaling pathway might represent a therapeutic target.

Entities:  

Keywords:  BRAF; CP = craniopharyngioma; CTNNB1; FFPE = formalin-fixed paraffin-embedded; GSK3-β = glycogen synthase kinase 3-β; GTR = gross-total resection; IHC = immunohistochemistry; NGS = next-generation sequencing; PFS = progression-free survival; RT = radiation therapy; RT-PCR = real-time polymerase chain reaction; Wnt/β-catenin; ada = adamantinomatous; craniopharyngioma; oncology; pap = papillary

Year:  2018        PMID: 30074466     DOI: 10.3171/2018.3.JNS172528

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  5 in total

1.  Treatment of Cystic Craniopharyngiomas: An Update.

Authors:  Federico Bianchi; Alberto Benato; Luca Massimi
Journal:  Adv Tech Stand Neurosurg       Date:  2022

2.  Adamantinomatous Craniopharyngioma in an Adult: A Case Report with NGS Analysis.

Authors:  Raid A Jastania; Muhammad Saeed; Hisham Al-Khalidi; Khalid AlQuthami; Tahani H Nageeti; Faisal A Al-Allaf; Kristoffer Valerie; Mohiuddin M Taher
Journal:  Int Med Case Rep J       Date:  2020-04-21

3.  Genomic and Transcriptomic Analyses Reveals ZNF124 as a Critical Regulator in Highly Aggressive Medulloblastomas.

Authors:  Zaili Luo; Xinran Dong; Jianzhong Yu; Yong Xia; Kalen P Berry; Rohit Rao; Lingli Xu; Ping Xue; Tong Chen; Yifeng Lin; Jiyang Yu; Guoying Huang; Hao Li; Wenhao Zhou; Q Richard Lu
Journal:  Front Cell Dev Biol       Date:  2021-02-18

4.  Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study.

Authors:  Naoto Mukada; Masahiko Tosaka; Nozomi Matsumura; Rei Yamaguchi; Masanori Aihara; Koji Isoda; Tetsuya Higuchi; Yoshito Tsushima; Hideaki Yokoo; Yuhei Yoshimoto
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

5.  Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma.

Authors:  Cynthia Kassab; Daniel Zamler; Carlos Kamiya-Matsuoka; Zoran Gatalica; Joanne Xiu; David Spetzler; Amy B Heimberger
Journal:  Clin Oncol Res       Date:  2019-06-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.